Tahir M Nawaz MN

OmicsDI

Browse
Submit Data
Databases
API

15 Results

Show all Save search Copy query

Show results for

Unknown (15)

Publication Date

Release Date

2009 (4)
2021 (3)
2025 (2)
2023 (2)
2022 (2)
2020 (1)
2018 (1)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

N'-[(1E)-1-(4-Chloro-phen-yl)ethyl-idene]formohydrazide.

The structure of the title compound, C(9)H(9)ClN(2)O, consists of centrosymmetric dimers due to inter-molecular N-H⋯O hydrogen bonding, forming R(2) (2)(8) ring motifs. The dihedral angle between the p-chloro-phenyl unit and the remaining heavy-atom group is 6.77 (17)°.

S-EPMC2970209 | biostudies-literature

N'-[(E)-(5-Methyl-furan-2-yl)methyl-idene]formohydrazide.

The title compound, C(7)H(8)N(2)O(2), is almost planar (r.m.s. deviation for non-H atoms = 0.029 Å). In the crystal, inversion dimers linked by pairs of N-H⋯O hydrogen bonds generate an R(2) (2)(8) ring motif.

S-EPMC2970214 | biostudies-literature

N'-[(E)-1-(3-Fluoro-phen-yl)ethyl-idene]formohydrazide.

In the title compound, C(9)H(9)FN(2)O, the dihedral angle between the fluoro-benzene ring and the mean plane of the side chain is 15.59 (14)°. In the crystal, the mol-ecules form inversion dimers linked by pairs of N-H⋯O hydrogen bonds, resulting in R(2) (2)(8) loops. These dimers are reinforced by ...

S-EPMC2971114 | biostudies-literature

3-Hydr-oxy-N'-[(Z)-(5-methyl-2-fur-yl)methyl-idene]naphthalene-2-carbo-hydrazide.

The asymmetric unit of title compound, C(17)H(14)N(2)O(3), contains three independent mol-ecules. In one of these mol-ecules, the 5-methyl-2-furyl group is disordered over two sets of sites with an occupancy ratio of 0.747 (3):0.253 (3). In the two ordered mol-ecules, the furan and naphthalene rings...

S-EPMC2971404 | biostudies-literature

Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.

The bromodomain containing protein 4 (BRD4) recognizes acetylated histone proteins and plays numerous roles in the progression of a wide range of cancers, due to which it is under intense investigation as a novel anti-cancer drug target. In the present study, we performed three-dimensional quantitat...

S-EPMC6099705 | biostudies-literature

Physiological insights into sulfate and selenium interaction to improve drought tolerance in mung bean.

The present study involved two pot experiments to investigate the response of mung bean to the individual or combined SO₄ ^2- and selenate application under drought stress. A marked increment in biomass and NPK accumulation was recorded in mung bean seedlings fertilized with var...

S-EPMC8140040 | biostudies-literature

Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.

Background

There is low-certainty evidence on the impact of extended pharmacological prophylaxis on venous thromboembolism-associated morbidity and mortality. The aim of this study was to determine the efficacy and safety of extended prophylaxis after major abdominopelvic surgery for the pre...

S-EPMC11894929 | biostudies-literature

Dexamethasone in Hospitalized Patients with Covid-19.

Background

Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

Methods

In this controlled, open-label trial comparing a range of poss...

S-EPMC7383595 | biostudies-literature

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Background

Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.

Methods

In this randomized, controlled, open-label platform trial c...

S-EPMC7556338 | biostudies-literature

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.